adplus-dvertising
Connect with us

Business

Canadian company's COVID-19 vaccine candidate begins clinical trial in Australia – CTV News

Published

 on


TORONTO —
Canadian company Symvivo Corporation says it has begun clinical trials for its oral COVID-19 vaccine.

The clinical-stage biotechnology company based in Burnaby, B.C. announced on Monday the enrolment and dosing of the first healthy volunteer in its bacTRL-Spike COVID-19 Phase I clinical trial in Australia.

“We are exceptionally pleased to commence dosing of our oral DNA vaccine for COVID-19 as we continue scale-up and manufacturing activities for future clinical development,” Symvivo’s chief medical officer Eric Sievers said in a press release.

The company says bacTRL-Spike has two key advantages over other vaccines: it can be taken orally as a capsule instead of by injection, and it is stored at room temperature, bypassing cold-chain supply logistics.

Symvivo says these elements could change the COVID-19 vaccine landscape to allow for “simple, safe and fast distribution of a vaccine globally,” as individuals could self-administer the vaccine rather than requiring a trained medical professional.

“The rapidly advancing pandemic mandates innovative scientific approaches and we believe a safe, protective oral vaccine could transform the landscape of traditional vaccination approaches, eliminating the need for syringes, needles, and trained vaccinators,” Sievers said in the release.

The news of the vaccine trial comes after Symvivo said in October it was receiving up to $2.8 million from Canada’s National Research Council to support the clinical advancement of bacTRL-Spike.

According to the press release, the Phase I trial is being conducted in partnership with Nucleus Network in Brisbane, Australia. The study will evaluate safety and preliminary evidence of immunogenicity to SARS CoV-2 — the virus that causes COVID-19 — in response to bacTRL-Spike among healthy volunteers.

Symvivo said preliminary data is expected in early 2021.

Symvivo CEO and founder Alexander Graves told CTVNews.ca the vaccine candidate has a scientific and compliance benefit. He explained in a telephone interview on Monday that by taking the vaccine orally, it allows for a mucosal response in the intestine that can trigger signals to eliminate viruses in the body.

He says this gene therapy platform delivers plasmid DNA that enables a patient’s own cells to produce therapeutic proteins that work to clear harmful virus particles from healthy tissues.

“Your mucosal immune response is really the first line of defense against viruses and other infectious diseases, and we have demonstrated the ability in our preclinical models to produce a mucosal response in addition to traditional systemic immune responses that other vaccines can induce,” Graves said.

As an oral capsule that can be kept at room temperature, Graves says bacTRL-Spike could actually eliminate supply logistics around a COVID-19 vaccine.

“When you could envision shipping this product [to] everybody’s home around the world so that people can take it without medical oversight, we can actually get a viable vaccine solution globally,” Graves said.

If the first phase of the clinical trials proves that bacTRL-Spike is safe to use, Graves said the company will then be able to evaluate whether an effective immune response against SARS-CoV-2 is generated.

“We’re going to be looking at the ability of the volunteer’s immune system to recognize the spike protein and mount an immune responses against it that we hope in the future can be protected against SARS-CoV-2 infection,” he said.

Let’s block ads! (Why?)

728x90x4

Source link

Continue Reading

Business

Canada Goose to get into eyewear through deal with Marchon

Published

 on

 

TORONTO – Canada Goose Holdings Inc. says it has signed a deal that will result in the creation of its first eyewear collection.

The deal announced on Thursday by the Toronto-based luxury apparel company comes in the form of an exclusive, long-term global licensing agreement with Marchon Eyewear Inc.

The terms and value of the agreement were not disclosed, but Marchon produces eyewear for brands including Lacoste, Nike, Calvin Klein, Ferragamo, Longchamp and Zeiss.

Marchon plans to roll out both sunglasses and optical wear under the Canada Goose name next spring, starting in North America.

Canada Goose says the eyewear will be sold through optical retailers, department stores, Canada Goose shops and its website.

Canada Goose CEO Dani Reiss told The Canadian Press in August that he envisioned his company eventually expanding into eyewear and luggage.

This report by The Canadian Press was first published Sept. 19, 2024.

Companies in this story: (TSX:GOOS)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

A timeline of events in the bread price-fixing scandal

Published

 on

 

Almost seven years since news broke of an alleged conspiracy to fix the price of packaged bread across Canada, the saga isn’t over: the Competition Bureau continues to investigate the companies that may have been involved, and two class-action lawsuits continue to work their way through the courts.

Here’s a timeline of key events in the bread price-fixing case.

Oct. 31, 2017: The Competition Bureau says it’s investigating allegations of bread price-fixing and that it was granted search warrants in the case. Several grocers confirm they are co-operating in the probe.

Dec. 19, 2017: Loblaw and George Weston say they participated in an “industry-wide price-fixing arrangement” to raise the price of packaged bread. The companies say they have been co-operating in the Competition Bureau’s investigation since March 2015, when they self-reported to the bureau upon discovering anti-competitive behaviour, and are receiving immunity from prosecution. They announce they are offering $25 gift cards to customers amid the ongoing investigation into alleged bread price-fixing.

Jan. 31, 2018: In court documents, the Competition Bureau says at least $1.50 was added to the price of a loaf of bread between about 2001 and 2016.

Dec. 20, 2019: A class-action lawsuit in a Quebec court against multiple grocers and food companies is certified against a number of companies allegedly involved in bread price-fixing, including Loblaw, George Weston, Metro, Sobeys, Walmart Canada, Canada Bread and Giant Tiger (which have all denied involvement, except for Loblaw and George Weston, which later settled with the plaintiffs).

Dec. 31, 2021: A class-action lawsuit in an Ontario court covering all Canadian residents except those in Quebec who bought packaged bread from a company named in the suit is certified against roughly the same group of companies.

June 21, 2023: Bakery giant Canada Bread Co. is fined $50 million after pleading guilty to four counts of price-fixing under the Competition Act as part of the Competition Bureau’s ongoing investigation.

Oct. 25 2023: Canada Bread files a statement of defence in the Ontario class action denying participating in the alleged conspiracy and saying any anti-competitive behaviour it participated in was at the direction and to the benefit of its then-majority owner Maple Leaf Foods, which is not a defendant in the case (neither is its current owner Grupo Bimbo). Maple Leaf calls Canada Bread’s accusations “baseless.”

Dec. 20, 2023: Metro files new documents in the Ontario class action accusing Loblaw and its parent company George Weston of conspiring to implicate it in the alleged scheme, denying involvement. Sobeys has made a similar claim. The two companies deny the allegations.

July 25, 2024: Loblaw and George Weston say they agreed to pay a combined $500 million to settle both the Ontario and Quebec class-action lawsuits. Loblaw’s share of the settlement includes a $96-million credit for the gift cards it gave out years earlier.

Sept. 12, 2024: Canada Bread files new documents in Ontario court as part of the class action, claiming Maple Leaf used it as a “shield” to avoid liability in the alleged scheme. Maple Leaf was a majority shareholder of Canada Bread until 2014, and the company claims it’s liable for any price-fixing activity. Maple Leaf refutes the claims.

This report by The Canadian Press was first published Sept. 19, 2024.

Companies in this story: (TSX:L, TSX:MFI, TSX:MRU, TSX:EMP.A, TSX:WN)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Business

TD CEO to retire next year, takes responsibility for money laundering failures

Published

 on

 

TORONTO – TD Bank Group, which is mired in a money laundering scandal in the U.S., says chief executive Bharat Masrani will retire next year.

Masrani, who will retire officially on April 10, 2025, says the bank’s, “anti-money laundering challenges,” took place on his watch and he takes full responsibility.

The bank named Raymond Chun, TD’s group head, Canadian personal banking, as his successor.

As part of a transition plan, Chun will become chief operating officer on Nov. 1 before taking over the top job when Masrani steps down at the bank’s annual meeting next year.

TD also announced that Riaz Ahmed, group head, wholesale banking and president and CEO of TD Securities, will retire at the end of January 2025.

TD has taken billions in charges related to ongoing U.S. investigations into the failure of its anti-money laundering program.

This report by The Canadian Press was first published Sept. 19, 2024.

Companies in this story: (TSX:TD)

The Canadian Press. All rights reserved.

Source link

Continue Reading

Trending